TOKYO, Nov 15, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Japan Ltd announced today that a TV commercial will be ...

1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...

Tokyo, Nov. 13 (Jiji Press)--Japan's Central Social Insurance Medical Council, which advises the health minister, approved ...

TOKYO (Kyodo) -- A single course of newly approved ... the treatment in Japan of early symptomatic Alzheimer's disease.

An estimated 4,500 prescriptions have been filled in 2024 so far, Iwatsubo said. About 80 percent of patients have mild cognitive impairment, the rest have mild dementia. Most are in their 70s, and ...

Steve Lee Hayes carved letters onto a pillar of a gate of a shrine in Shibuya and was arrested on suspicion of property ...

A 65-year-old American tourist has been arrested in Japan for carving letters into a wooden gate at a shrine in Tokyo.

Japan is seeing a record boom in tourism, but one recent visitor travelled more than the circumference of the earth to get ...

Now that summer has loosened its torrid grip, a trip to this outdoor museum in the western Tokyo suburbs is a perfect way to ...

The colorful blooms of azaleas light up public spaces and private gardens.

Eisai and Biogen’s Alzheimer’s disease therapy Leqembi is due to be launched in Japan, its second market, on 20th December, and will be priced quite a lot lower there than in the US.

Eisai has filed for approval in Japan for tasurgratinib, its small-molecule fibroblast growth factor (FGF) receptor inhibitor, as a treatment for biliary tract cancers with FGFR2 gene fusion ...